Get to know our clinical trials
AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B)
THE AIM OF THIS STUDY IS TO DETERMINE THE EFFICACY OF TRIPLE THERAPY (TRELEGY) IN IMPROVING CLINICAL CONTROL IN THE GOLD B SUBGROUP OF COPD PATIENTS COMPARED TO THE USUAL DUAL THERAPY IN THESE PATIENTS.
Technical Summary
- AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B)
- Code EudraCT: 2023-507304-32
- Protocol number: ANTES B
- Promoter: Fundació Privada Món Clínic Barcelona
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.